A phase 1 dose-escalation study of the safety and pharmacokinetics of XL418 administered orally daily to subjects with solid tumors
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2008
At a glance
- Drugs XL 418 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Exelixis
- 09 Jan 2008 Status changed from recruiting to suspended.
- 21 Jun 2007 New trial record.